FDA grants accelerated approval to Bristol Myers' iberdomide for relapsed or refractory multiple myeloma

The U.S. Food and Drug Administration has issued an accelerated approval for iberdomide, a small-molecule therapy developed by Bristol Myers Squibb.

The approval targets patients with multiple myeloma whose disease has returned or who no longer respond to existing treatments, addressing an unmet need in this heavily pre-treated population.

Iberdomide will be marketed under the brand name Zenbexus and is expected to be available pending further confirmatory studies required by the agency.

The decision reflects the FDA's ongoing effort to expedite options for cancers with limited therapeutic alternatives.